The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 28, 2018

Filed:

Dec. 09, 2013
Applicant:

Matinas Biopharma, Inc., Bedminster, NJ (US);

Inventors:

George Bobotas, Tarpon Springs, FL (US);

Abdel Aziz Fawzy, Boynton Beach, FL (US);

Assignee:

MATINAS BIOPHARMA INC., Bedminster, NJ (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/201 (2006.01); A61K 31/202 (2006.01); A61K 31/40 (2006.01); A61K 31/232 (2006.01); A61K 9/48 (2006.01);
U.S. Cl.
CPC ...
A61K 31/201 (2013.01); A61K 9/4825 (2013.01); A61K 9/4858 (2013.01); A61K 31/202 (2013.01); A61K 31/232 (2013.01); A61K 31/40 (2013.01); Y10S 514/893 (2013.01);
Abstract

Orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-fatty acids, salts or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the ratio of DHA to EPA (DHA:EPA) is less than 1:20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore.


Find Patent Forward Citations

Loading…